Recently, the Bank of China Suzhou Branch successfully landed a 10 million yuan BOC epidemic prevention loan, specifically supporting the research and development company "Extra Cardiopulmonary Support (ECMO) Project"-Suzhou Xinqing Medical Technology Co., Ltd. (hereinafter referred to as "Xinqing Medical").

         It is understood that Xinqing Medical is developing a new generation of ECMO products (extracorporeal membrane lung oxygenation system, commonly known as Ye Ke membrane or artificial heart-lung instrument), which can provide critically ill patients with respiratory and circulatory failure caused by new coronavirus or other viral pneumonia. Effective treatment. According to industry statistics, the ECMO market is monopolized by the world's medical device companies. The domestically available ECMO equipment is small in number and imported, and the price is expensive. The current domestic independent research and development needs are very urgent. The in vitro artificial heart product developed by Xinqing Medical Institute is expected to be put on the market in 2022, and its ECMO products will be promoted in clinical applications to fill the gap in the domestic market. After learning about Xinqing Medical ’s R & D financing needs for the ECMO project, the new branch of the Suzhou Branch of the BOC Suzhou Branch responded quickly and quickly. With the strong support of the Pratt & Whitney Financial Division and the Risk Management Department of the branch, the project was successfully completed within 1 week. Pre-loan investigation and credit approval, and successfully issued 10 million yuan of epidemic prevention loans to support Xinqing Medical's medical device R & D and production.